N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin

Aurelie Lenglet (1, 2) , Sophie Liabeuf (1, 2) , Sandra Bodeau (1, 2) , Loïc Louvet (2) , Aurelien Mary (2) , Agnes Boullier (2) , Anne Sophie Lemaire-Hurtel (1) , Alexia Jonet (3) , Pascal Sonnet (4) , Saïd Kamel (2) , Ziad A. Massy (5, 6, 7)

1 CHU Amiens-Picardie
2 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517
3 LG2A - Laboratoire de Glycochimie, des Antimicrobiens et des Agro-ressources - UMR CNRS 7378
4 AGIR - Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
5 Hôpital Ambroise Paré [AP-HP]
6 U1018 (Équipe 5) - Épidémiologie et recherches translationnelles sur les maladies rénales et cardiovasculaires (EPREC)
7 CESP - Centre de recherche en épidémiologie et santé des populations

N-methyl-2-pyridone-5-carboxamide (2PY, a major metabolite of nicotinamide, NAM) was recently identified as a uremic toxin. Recent interventional trials using NAM to treat high levels of phosphorus in end-stage renal disease have highlighted new potential uremic toxicities of 2PY. In the context of uremia, the accumulation of 2PY could be harmful-perhaps by inhibiting poly (ADP-ribose) polymerase-1 activity. Here, we review recently published data on 2PY's metabolism and toxicological profile.

Domaines: Sciences du Vivant [q-bio]

Aurelie Lenglet, Sophie Liabeuf, Sandra Bodeau, Loïc Louvet, Aurelien Mary, et al.. N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. Toxins, 2016, 8 (11), ⟨10.3390/toxins8110339⟩. ⟨hal-03568256⟩